Article

Regenera buys Advanced Ocular Systems

Marblehead, MA—A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

Marblehead, MA-A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

AOS, which will own 45% of Regenera, is led by Ken Taylor, OD, its president and chief executive officer, and a frequent consultant to ophthalmic companies. Founded in early 2005, AOS develops and commercializes devices to treat refractive disorders such as presbyopia.

The merger creates a new global ophthalmic company with a strong pipeline of refractive and retinal technology and products and emerging revenues from existing licensed products, the companies said. The new company will be based in Marblehead, MA, with research and development and administrative operations in Australia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.